Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: FN Stockholm
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ChronTech Pharma AB

+ Add to Watchlist

CTEC:SS

0.0130 SEK 0.0010 8.33%

As of 12:00:00 ET on 02/27/2015.

Snapshot for ChronTech Pharma AB (CTEC)

Open: 0.0120 Day's Range: 0.0110 - 0.0130 Volume: 373,725
Previous Close: 0.0120 52wk Range: 0.0110 - 0.2300 1-Yr Rtn: -93.50%

Stock Chart for CTEC

No chart data available.
  • CTEC:SS 0.0130
  • 1D
  • 1M
  • 1Y
0.0120
Interactive CTEC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CTEC

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. OMX -
Earnings Per Share (ttm) -0.0672
Est. EPS -
Est. PEG Ratio -
Market Cap (M SEK) 14.24
Shares Outstanding (M) 1,095.68
30 Day Average Volume 3,003,518
Price/Book (mrq) 0.7777
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CTEC

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for CTEC

ChronTech Pharma AB is a biomedical company. The Company develops therapies for chronic diseases. The Company develops therapeutic DNA-vaccines drugs against chronic hepatitis C virus and hepatitis B-virus infections. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines.

Anders VahlneCEO/Head:R&DAsa EkstrandChief Financial Officer
More Company Profile & Key Executives for CTEC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil